The giants in AI + pharmaceuticals have renewed their collaboration, with Immunai securing $37.5 million this round, pushing the oncology track to new heights.

View Original
CryptoFrontier
AstraZeneca Expands AI Partnership with Immunai Through 2027
AstraZeneca has expanded its partnership with New York-based AI biotech company Immunai through 2027, according to Calcalist. Under the expanded agreement, Immunai is eligible to receive up to $37.5 million in 2026 and 2027 as the drugmaker continues integrating its platform into oncology drug
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin